New drug PT0511 targets tough KRAS cancers in early trial

NCT ID NCT07300150

First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 24 times

Summary

This early-phase study tests a new drug called PT0511 in about 195 adults with advanced solid tumors that have a KRAS mutation or amplification, including colorectal, pancreatic, and lung cancers. The main goals are to check safety, find the best dose, and see how the drug works alone or with cetuximab for colorectal cancer. Participants must have tried at least one prior treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dana-Farber/Massachusetts General Hospital, Inc

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Email: •••••@•••••

  • NEXT Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

    Contact Email: •••••@•••••

  • New Experimental Therapeutics of San Antonio LLC

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact Email: •••••@•••••

  • START - South Texas Accelerated Research Therapeutics, LLC

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact Email: •••••@•••••

  • START Mountain Region

    RECRUITING

    West Valley City, Utah, 84119, United States

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.